TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NewcelX ( (NCEL) ) has issued an update.
NewCelX Ltd., previously known as NLS Pharmaceutics Ltd., has undergone a significant change in its accounting firm as part of its merger with Kadimastem Ltd. On November 20, 2025, Ernst & Young (EY) was appointed as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. This decision follows the dismissal of CBIZ CPAs, who had replaced Marcum LLP earlier in September 2025. The transition to EY is a strategic move post-merger, aligning the company’s accounting practices with its new operational structure.
More about NewcelX
Average Trading Volume: 182,857
Technical Sentiment Signal: Sell
Current Market Cap: $1.41M
Learn more about NCEL stock on TipRanks’ Stock Analysis page.